The Cooper Companies, Inc. $COO Shares Sold by Clearbridge Investments LLC

Posted by Francis Steltz on Jun 11th, 2026

Clearbridge Investments LLC lessened its position in The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 40.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 193,305 shares of the medical device company’s stock after selling 131,383 shares during the period. Clearbridge Investments LLC’s holdings in Cooper Companies were worth $15,843,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of COO. New York Life Investment Management LLC boosted its holdings in shares of Cooper Companies by 0.6% during the fourth quarter. New York Life Investment Management LLC now owns 27,344 shares of the medical device company’s stock worth $2,241,000 after purchasing an additional 158 shares during the last quarter. Root Financial Partners LLC boosted its holdings in shares of Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock worth $26,000 after purchasing an additional 162 shares during the last quarter. Allworth Financial LP boosted its holdings in shares of Cooper Companies by 14.1% during the fourth quarter. Allworth Financial LP now owns 1,355 shares of the medical device company’s stock worth $111,000 after purchasing an additional 167 shares during the last quarter. Mesirow Financial Investment Management Inc. increased its stake in shares of Cooper Companies by 1.3% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 14,017 shares of the medical device company’s stock valued at $961,000 after acquiring an additional 175 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Cooper Companies by 13.9% during the 4th quarter. Blue Trust Inc. now owns 1,515 shares of the medical device company’s stock valued at $124,000 after acquiring an additional 185 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Recent commentary highlighted The Cooper Companies as a strong long-term growth name, with Zacks calling it a top growth stock and Seeking Alpha noting potential for an analyst upgrade as valuation improves. Article Title
Positive Sentiment: Analysts and market commentary also pointed to the company’s demand growth and prior quarterly earnings beat, which can reinforce confidence in revenue momentum. Article Title
Neutral Sentiment: One article noted that Cooper has strong revenue growth, especially in CooperVision, but also said litigation charges tied to embryo culture media recalls have weighed on reported profitability; these issues do not appear to change the long-term outlook materially. Article Title
Negative Sentiment: Some analysis still argues The Cooper Companies needs stronger return on equity and profit margins, which may temper enthusiasm despite solid sales trends. Article Title

Wall Street Analyst Weigh In

A number of research analysts have recently commented on COO shares. Robert W. Baird dropped their price objective on shares of Cooper Companies from $98.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. JPMorgan Chase & Co. decreased their price target on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a report on Friday, June 5th. Wells Fargo & Company reiterated a “sell” rating and issued a $66.00 price target (down from $82.00) on shares of Cooper Companies in a report on Friday, June 5th. Barclays lifted their price target on shares of Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, March 6th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $82.64.

Read Our Latest Analysis on Cooper Companies

Cooper Companies Stock Down 1.4%

Shares of NASDAQ COO opened at $67.69 on Thursday. The Cooper Companies, Inc. has a 12-month low of $58.89 and a 12-month high of $89.83. The company has a market cap of $13.20 billion, a P/E ratio of 57.36, a P/E/G ratio of 1.80 and a beta of 0.87. The company has a current ratio of 1.27, a quick ratio of 0.78 and a debt-to-equity ratio of 0.23. The stock has a fifty day moving average price of $64.94 and a 200 day moving average price of $74.45.

Cooper Companies (NASDAQ:COO – Get Free Report) last announced its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.11. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The firm’s quarterly revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.96 EPS. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. Research analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Cooper Companies Profile

(Free Report)

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.